1. Blood pressure after treatment with sodium–glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score‐matched models
- Author
-
Hareaki Yamamoto, Akira Kanamori, Daisuke Suzuki, Masao Toyoda, Nobuo Hatori, Hisakazu Degawa, Kazuyoshi Sato, Takayuki Furuki, Hiroyuki Sakai, Kouta Aoyama, Kouichi Tamura, Keiichi Chin, Masahiro Takihata, Shun Ito, Fuyuki Minagawa, Masahiro Hayashi, Toshimasa Hishiki, Kohsuke Minamisawa, Yoshiro Suzuki, Hiroshi Takeda, Togo Aoyama, Hideo Machimura, Yutaka Hatori, Shinichi Umezawa, Masaaki Miyakawa, Yoshiro Hamada, Tomoya Umezono, and Kazuo Kobayashi
- Subjects
Blood Glucose ,Male ,medicine.medical_specialty ,Mean arterial pressure ,Diabetic Cardiomyopathies ,Endocrinology, Diabetes and Metabolism ,Urology ,Renal function ,Blood Pressure ,Diabetic nephropathy ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,Internal Medicine ,medicine ,Humans ,Diabetic Nephropathies ,030212 general & internal medicine ,Renal Insufficiency, Chronic ,Propensity Score ,Sodium-Glucose Transporter 2 Inhibitors ,Retrospective Studies ,Glycated Hemoglobin ,business.industry ,Articles ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Clinical Science and Care ,Blood pressure ,Diabetes Mellitus, Type 2 ,Sodium–glucose cotransporter 2 Inhibitors ,Propensity score matching ,Albuminuria ,Original Article ,Female ,medicine.symptom ,business ,Biomarkers ,Follow-Up Studies ,Glomerular Filtration Rate ,Kidney disease - Abstract
Aims/Introduction Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve renal outcome in patients with type 2 diabetes mellitus, but the mechanism is not fully understood. The aim of this retrospective study was to assess the association of achieved blood pressure with renal outcomes in Japanese type 2 diabetes mellitus patients with chronic kidney disease. Materials and Methods We assessed 624 Japanese type 2 diabetes mellitus patients with chronic kidney disease taking SGLT2i for >1 year. The patients were classified as those with post‐treatment mean arterial pressure (MAP) of ≥92 mmHg (n = 344) and those with MAP of, Incidence of renal composite outcome and changes in logarithmic value of the albumin‐to‐creatinine ratio and estimated glomerular filtration rate.
- Published
- 2020
- Full Text
- View/download PDF